摘要
目的探讨血脂康对急性冠状动脉综合征患者基质金属蛋白酶2和9的影响。方法30例急性冠状动脉综合征患者住院后服用血脂康,在服药前、服药后7天和30天分别收集静脉血1 mL,以检测基质金属蛋白酶2和9及相应酶原。正常对照组为25例健康自愿者。结果与正常对照组相比,急性冠状动脉综合征患者基质金属蛋白酶2及酶原明显增高(P<0.01)。与服药前相比,服用血脂康后7天基质金属蛋白酶2和9及相应酶原无明显变化,服药30天后基质金属蛋白酶2下降(P<0.05),基质金属蛋白酶2酶原、基质金属蛋白酶9及酶原无明显变化(P>0.05)。结论急性冠状动脉综合征患者血清基质金属蛋白酶2及酶原明显增高,血脂康可以降低基质金属蛋白酶2。
Aim To investigate the effect of Xuezhikang on matrix metalloproteinase-2, 9 （MMP-2, 9）in acute coronary syndromes （ACS） patients, Methods Xuezhikang were administered in thirty ACS patients. MMP-2, 9 and pro MMP-2, 9 were evaluated before administration, after 7 days and 30 days by SDS-PAGE enzymograph. The normal control group included twenty-five volunteers. Results Serum MMP-2 and pro MMP-2 elevated significantly in ACS group compared with control group （P〈0.01）. No differences in MMP-2, 9 and pro MMP-2, 9 existed before administration and after 7 days in patients with ACS. Senun MMP-2 after 30 days in ACS patients elevated significantly than that before administration （ P 〈 0.05 ）. Conclusions Serum MMP-2 and pro MMP-2 elevated significantly in ACS patients and Xuezhikang could decrease the levels of serum MMP-2 and pro MMP-2.
出处
《中国动脉硬化杂志》
CAS
CSCD
2006年第7期623-624,共2页
Chinese Journal of Arteriosclerosis
基金
吉林省科技厅资助课题(20050408-5)
